drugset / Trial / NCT00965094
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard CNI-based regimen in de novo renal transplant patients.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2 mg | — |
| Comparator | Tacrolimus | Small molecule | — | — |
| Background | Basiliximab | Monoclonal antibody | 20 mg | Intravenous |
| Background | Mycophenolate Sodium | Unknown | 1440 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |